Share Email Print
cover

Proceedings Paper

Photodynamic therapy for skin cancer
Author(s): Masoud Panjehpour; Clark E. Julius; Donald L. Hartman
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Photodynamic therapy was used to treat 111 lesions in 27 cases with squamous and basal cell carcinoma. There were 82 squamous cell carcinomas and 29 basal cell carcinomas. Photofrin was administered intravenously at either 1.0 mg/kg or 0.75 mg/kg. An argon/dye laser was used to deliver 630 nm light to the lesion superficially at either 215 J/cm2 or 240 J/cm2. In some cases the laser light was delivered both superficially and interstitially. The laser light was delivered two to four days after the Photofrin injection. There were 105 complete responses and 5 partial responses. One patient was lost to follow-up. Among partial responses were basal cell carcinoma on the tip of the nose and morphea basal cell carcinoma of the left cheek. Another partial response occurred in a basal cell carcinoma patient where insufficient margins were treated due to the proximity to the eye. When 0.75 mg/kg drug dose was used, the selectivity of tumor necrosis was improved. Decreased period of skin photosensitivity was documented in some cases.

Paper Details

Date Published: 2 April 1996
PDF: 3 pages
Proc. SPIE 2675, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V, (2 April 1996); doi: 10.1117/12.237545
Show Author Affiliations
Masoud Panjehpour, Thompson Cancer Survival Ctr. (United States)
Clark E. Julius, Thompson Cancer Survival Ctr. (United States)
Donald L. Hartman, Thompson Cancer Survival Ctr. (United States)


Published in SPIE Proceedings Vol. 2675:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top